Bristol-Myers Squibb Co (NYSE:BMY) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 74,111,887 shares, a growth of 21.6% from the February 15th total of 60,972,039 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average daily volume of 24,159,361 shares, the days-to-cover ratio is presently 3.1 days.

Hedge funds have recently modified their holdings of the stock. American Century Companies Inc. raised its position in Bristol-Myers Squibb by 34.5% during the 4th quarter. American Century Companies Inc. now owns 4,390,458 shares of the biopharmaceutical company’s stock valued at $228,216,000 after purchasing an additional 1,125,410 shares during the last quarter. Sowell Financial Services LLC raised its position in Bristol-Myers Squibb by 18.5% during the 4th quarter. Sowell Financial Services LLC now owns 16,880 shares of the biopharmaceutical company’s stock valued at $877,000 after purchasing an additional 2,641 shares during the last quarter. Norges Bank bought a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $797,038,000. Actinver Wealth Management Inc. bought a new position in Bristol-Myers Squibb during the 4th quarter valued at approximately $879,000. Finally, Griffin Asset Management Inc. raised its position in Bristol-Myers Squibb by 1.7% during the 4th quarter. Griffin Asset Management Inc. now owns 200,754 shares of the biopharmaceutical company’s stock valued at $10,435,000 after purchasing an additional 3,337 shares during the last quarter. Institutional investors own 73.35% of the company’s stock.

Shares of BMY stock opened at $49.96 on Monday. The stock has a market cap of $80.88 billion, a P/E ratio of 12.55, a P/E/G ratio of 2.22 and a beta of 0.81. Bristol-Myers Squibb has a 1-year low of $44.30 and a 1-year high of $67.44. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.61 and a quick ratio of 1.50.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. Bristol-Myers Squibb’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.68 EPS. As a group, equities research analysts expect that Bristol-Myers Squibb will post 4.15 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

A number of equities analysts have recently issued reports on BMY shares. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Tuesday, November 27th. BMO Capital Markets cut their price objective on Bristol-Myers Squibb to $56.00 and set a “market perform” rating for the company in a report on Tuesday, November 27th. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. Credit Suisse Group reiterated a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. Finally, Morgan Stanley set a $54.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, December 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $59.40.

COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Short Interest Update” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/bristol-myers-squibb-co-bmy-short-interest-update/2898135.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Current Ratio

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.